All In Biotech

Drug Trial Radar · NCT03888066

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin Angiotensin Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure (DIAMOND)

Last checked: Nov 20, 2026Latest source record: Feb 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,195 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,195

Actual

Start

Apr 24, 2019

Primary completion

Sep 2, 2021

Study completion Sep 2, 2021

Sponsor

Lead sponsor
Vifor Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Syneos Health
First posted
Mar 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.

Conditions

  • Hyperkalemia

Interventions

  • PatiromerDrug

    The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be decreased to a minimum of 0 packets/day. Doses of patiromer will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).

  • PlacebosDrug

    The starting dose of placebo will be 1 packet/day and may be taken either with food or without food. Based upon the placebo treatment algorithm placebo may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, placebo may be decreased to a minimum of 0 packets/day. Doses of placebo will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in Serum K+ Levels From BaselineTime frame: Mean duration of exposure: 227.9 days for Patiromer and 234.5 days for Placebo

Locations

415 sites in 21 countries. Site status is shown where the registry gives one.

  • Investigator Site 11-080

    Alexander City, Alabama

  • Investigator Site 11-041

    Huntsville, Alabama

  • Investigator Site 11-153

    Phoenix, Arizona

  • Investigator Site 11-097

    Tucson, Arizona

  • Investigator Site 11-052

    Bakersfield, California

  • Investigator Site 11-174

    Fremont, California

  • Investigator Site 11-136

    Fresno, California

  • Investigator Site 11-102

    Huntington Beach, California

  • Investigator Site 11-162

    La Jolla, California

  • Investigator Site 11-048

    La Mesa, California

  • Investigator Site 11-111

    Laguna Hills, California

  • Investigator Site 11-017

    Long Beach, California

  • Investigator Site 11-128

    Northridge, California

  • Investigator Site 11-035

    Pasadena, California

  • Investigator Site 11-044

    Sacramento, California

  • Investigator Site 11-135

    San Diego, California

  • Investigator Site 11-086

    San Diego, California

  • Investigator Site 11-112

    Santa Ana, California

  • Investigator Site 11-101

    Stockton, California

  • Investigator Site 11-047

    Thousand Oaks, California

  • Investigator Site 11-057

    Van Nuys, California

  • Investigator Site 11-058

    West Hills, California

  • Investigator Site 11-095

    Aurora, Colorado

  • Investigator Site 11-168

    Altamonte Springs, Florida

  • Investigator Site 11-106

    Boynton Beach, Florida

  • Investigator Site 11-028

    Brandon, Florida

  • Investigator Site 11-003

    Doral, Florida

  • Investigator Site 11-138

    Gainesville, Florida

  • Investigator Site 11-164

    Greenacres City, Florida

  • Investigator Site 11-078

    Homestead, Florida

  • Investigator Site 11-004

    Jacksonville, Florida

  • Investigator Site 11-179

    Jacksonville, Florida

  • Investigator Site 11-122

    Medley, Florida

  • Investigator Site 11-115

    Miami, Florida

  • Investigator Site 11-125

    Miami, Florida

  • Investigator Site 11-005

    Miami, Florida

  • Research Site 11-001

    Miami Lakes, Florida

  • Research Site 11-002

    Miami Lakes, Florida

  • Investigator Site 11-032

    North Miami Beach, Florida

  • Investigator Site 11-171

    Orlando, Florida

Showing 40 of 415 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.